News coverage about Envision Healthcare (NYSE:EVHC) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Envision Healthcare earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.4418422849565 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

A number of equities analysts have issued reports on EVHC shares. Jefferies Group set a $41.00 price target on Envision Healthcare and gave the company a “buy” rating in a research note on Tuesday, December 19th. Robert W. Baird set a $45.00 price target on Envision Healthcare and gave the company a “buy” rating in a research note on Monday, February 26th. Cantor Fitzgerald reiterated a “hold” rating and set a $37.00 price target on shares of Envision Healthcare in a research note on Friday, January 5th. Stephens reiterated a “hold” rating and set a $34.00 price target on shares of Envision Healthcare in a research note on Wednesday, January 10th. Finally, ValuEngine downgraded Envision Healthcare from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. One analyst has rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. Envision Healthcare currently has an average rating of “Hold” and an average target price of $42.57.

Envision Healthcare (NYSE:EVHC) opened at $39.41 on Thursday. Envision Healthcare has a 1 year low of $23.77 and a 1 year high of $66.39. The company has a debt-to-equity ratio of 0.87, a quick ratio of 3.38 and a current ratio of 3.40. The company has a market cap of $5,260.00, a P/E ratio of 18.42, a price-to-earnings-growth ratio of 1.09 and a beta of 0.48.

Envision Healthcare (NYSE:EVHC) last posted its earnings results on Tuesday, February 27th. The company reported $0.59 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.45 by $0.14. Envision Healthcare had a negative net margin of 2.52% and a positive return on equity of 4.62%. The firm had revenue of $2 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter last year, the firm earned $1.15 EPS. The company’s quarterly revenue was up 68.0% compared to the same quarter last year. sell-side analysts forecast that Envision Healthcare will post 3.34 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2018/03/14/envision-healthcare-evhc-getting-somewhat-positive-news-coverage-report-shows.html.

About Envision Healthcare

Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.

Insider Buying and Selling by Quarter for Envision Healthcare (NYSE:EVHC)

Receive News & Ratings for Envision Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.